… versus a placebo in Japanese patients with NSCLC and cachexia; … LBM in Japanese patients
with NSCLC and cachexia. … LBM and body weight in Japanese patients with NSCLC and …

… general picture of medically treated lung cancer patients in Japan, including descriptive
statistics, treatment choice, and prognosis. About two-thirds of patients were classified as stage …

… -stage lung cancer is only indicated for selected patients with … 90s in Japan, the early detection
of small-sized early lung … is a highly malignant disease, according to our results, patients …

… Therapy (FACT)–General [31] have been used in many clinical trials to assess the QoL of
patients worldwide, and we have developed and validated Japanese versions of these tests for …

… cell lung cancer (NSCLC), despite initial response to EGFR-tyrosine kinase inhibitors (TKIs).
In Japan, … method used for re-biopsy to identify patients eligible for treatment. We aimed to …

… Patients with lung cancer who are selected by EGFR mutations have longer progression-free …
Furthermore, our pooled analyses based on individual patient data from seven Japanese …

… patients with lung cancer, aged up to 50 years, were enrolled from among the 11,663 patients
registered in the Japanese Lung Cancer … with those of 10,959 patients older than 50 years. …

… Patients One hundred and forty-one Japanese patients with untreated SCLC were diagnosed
between April 2006 and March 2011 at Kyoto University Hospital. Of these, 19 received …

… Japan, 26% to 49% of patients with NSCLC are EGFR mutation-positive, higher than in
non-East Asians [9], [10]. In most Japanese patients … options for Japanese patients with wild-type …

… 27.7% of the Japanese population. By 2065, the average age of Japanese men and women
is … Lung cancer is the leading cause of cancer death in Japan, and predominantly affects the …